Abstract
Osteoporosis (OP) is a systemic skeletal disease leading to fragility fractures and is a major health issue globally. WNT/β-catenin signaling regulates bone-remodeling processes and plays vital roles in OP development. However, the underlying regulatory mechanisms behind WNT/β-catenin signaling in OP requires clarification, as further studies are required to identify novel alternate therapeutic agents to improve OP. Here we report that fibronectin 1 (FN-1) promoted differentiation and mineralization of osteoblasts by activating WNT/β-catenin pathway, in cultured pre-osteoblasts. With isobaric tags for relative and absolute quantitation labeling proteomics analysis, we investigated protein changes in bone samples from OP patients and normal controls. FN-1 accumulated in osteoblasts in bone samples from OP patients and age-related OP mice compared to control group. In addition, we observed that integrin β1 (ITGB1) acts as an indispensable signaling molecule for the interplay between FN-1 and β-catenin, and that FN-1 expression increased, but ITGB1 expression decreased in osteoblasts during OP progression. Therefore, our study reveals a novel explanation for WNT/β-catenin pathway inactivation in OP pathology. Supplying of FN-1 and ITGB1 may provide a potential therapeutic strategy in improving bone formation during OP.
Access options
Subscribe to Journal
Get full journal access for 1 year
$499.00
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.





References
- 1.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–95.
- 2.
Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010–18.
- 3.
Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:87.
- 4.
Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393:364–76.
- 5.
Corrado A, Sanpaolo ER, Di Bello S, Cantatore FP. Osteoblast as a target of anti-osteoporotic treatment. Postgrad Med. 2017;129:858–65.
- 6.
An J, Yang H, Zhang Q, Liu C, Zhao J, Zhang L, et al. Natural products for treatment of osteoporosis: the effects and mechanisms on promoting osteoblast-mediated bone formation. Life Sci. 2016;147:46–58.
- 7.
Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179–92.
- 8.
Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469–80.
- 9.
Morvan F, Boulukos K, Clement-Lacroix P, Roman Roman S, Suc-Royer I, Vayssiere B, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21:934–45.
- 10.
Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751–64.
- 11.
Ge L, Cui Y, Liu B, Yin X, Pang J, Han J. ERalpha and Wnt/betacatenin signaling pathways are involved in angelicindependent promotion of osteogenesis. Mol Med Rep.2019;19:3469–76.
- 12.
Liu SL, Zhou YM, Tang DB, Zhou N, Zheng WW, Tang ZH, et al. LGR6 promotes osteogenesis by activating the Wnt/beta-catenin signaling pathway. Biochem Biophys Res Commun. 2019;519:1–7.
- 13.
Inoue D. Sequential treatment of osteoporosis with anti-sclerostin. Clin Calcium. 2019;29:363–9.
- 14.
Maurer LM, Ma W, Mosher DF. Dynamic structure of plasma fibronectin. Crit Rev Biochem Mol Biol. 2015;51:213–27.
- 15.
Schwarzbauer JE, DeSimone DW. Fibronectins, their fibrillogenesis, and in vivo functions. Cold Spring Harb Perspect Biol. 2011;3:a005041.
- 16.
Zollinger AJ, Smith ML. Fibronectin, the extracellular glue. Matrix Biol. 2017;60-61:27–37.
- 17.
Gao W, Liu Y, Qin R, Liu D, Feng Q. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line. Biochem Biophys Res Commun. 2016;476:35–41.
- 18.
Kimura E, Kanzaki T, Tahara K, Hayashi H, Hashimoto S, Suzuki A, et al. Identification of citrullinated cellular fibronectin in synovial fluid from patients with rheumatoid arthritis. Mod Rheumatol. 2014;24:766–9.
- 19.
Doddapattar P, Gandhi C, Prakash P, Dhanesha N, Grumbach IM, Dailey ME, et al. Fibronectin splicing variants containing extra domain A promote atherosclerosis in mice through toll-like receptor 4. Arterioscler Thromb Vasc Biol. 2015;35:2391–400.
- 20.
Bentmann A, Kawelke N, Moss D, Zentgraf H, Bala Y, Berger I, et al. Circulating fibronectin affects bone matrix, whereas osteoblast fibronectin modulates osteoblast function. J Bone Miner Res. 2010;25:706–15.
- 21.
Sens C, Huck K, Pettera S, Uebel S, Wabnitz G, Moser M, et al. Fibronectins containing extradomain A or B enhance osteoblast differentiation via distinct integrins. J Biol Chem. 2017;292:7745–60.
- 22.
Brunner M, Millon-Fremillon A, Chevalier G, Nakchbandi IA, Mosher D, Block MR, et al. Osteoblast mineralization requires beta1 integrin/ICAP-1-dependent fibronectin deposition. J Cell Biol. 2011;194:307–22.
- 23.
Bielefeld KA, Amini-Nik S, Whetstone H, Poon R, Youn A, Wang J, et al. Fibronectin and beta-catenin act in a regulatory loop in dermal fibroblasts to modulate cutaneous healing. J Biol Chem. 2011;286:27687–97.
- 24.
Ecarot-Charrier B, Glorieux FH, van der Rest M, Pereira G. Osteoblasts isolated from mouse calvaria initiate matrix mineralization in culture. J Cell Biol. 1983;96:639–43.
- 25.
Kadler KE, Hill A, Canty-Laird EG. Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol. 2008;20:495–501.
- 26.
Grzesik WJ, Frazier CR, Shapiro JR, Sponseller PD, Robey PG, Fedarko NS. Age-related changes in human bone proteoglycan structure. Impact of osteogenesis imperfecta. J Biol Chem. 2002;277:43638–47.
- 27.
Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat. 2007;28:209–21.
- 28.
Moursi AM, Damsky CH, Lull J, Zimmerman D, Doty SB, Aota S, et al. Fibronectin regulates calvarial osteoblast differentiation. J Cell Sci. 1996;109:1369–80.
- 29.
Sun M, Chi G, Xu J, Tan Y, Xu J, Lv S, et al. Extracellular matrix stiffness controls osteogenic differentiation of mesenchymal stem cells mediated by integrin alpha5. Stem Cell Res Ther. 2018;9:52.
- 30.
Lai CF, Cheng SL. Alphavbeta integrins play an essential role in BMP-2 induction of osteoblast differentiation. J Bone Miner Res. 2005;20:330–40.
- 31.
Popov C, Radic T, Haasters F, Prall WC, Aszodi A, Gullberg D, et al. Integrins alpha2beta1 and alpha11beta1 regulate the survival of mesenchymal stem cells on collagen I. Cell Death Dis. 2011;2:e186.
- 32.
Hamidouche Z, Fromigue O, Ringe J, Haupl T, Vaudin P, Pages JC, et al. Priming integrin alpha5 promotes human mesenchymal stromal cell osteoblast differentiation and osteogenesis. Proc Natl Acad Sci USA. 2009;106:18587–91.
- 33.
Brown AC, Dysart MM, Clarke KC, Stabenfeldt SE, Barker TH. Integrin alpha3beta1 binding to fibronectin is dependent on the ninth type III repeat. J Biol Chem. 2015;290:25534–47.
- 34.
Robinson EE, Foty RA, Corbett SA. Fibronectin matrix assembly regulates alpha5beta1-mediated cell cohesion. Mol Biol Cell. 2004;15:973–81.
- 35.
Koshida S, Kishimoto Y, Ustumi H, Shimizu T, Furutani-Seiki M, Kondoh H, et al. Integrinalpha5-dependent fibronectin accumulation for maintenance of somite boundaries in zebrafish embryos. Dev Cell. 2005;8:587–98.
- 36.
Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem. 2005;280:41342–51.
- 37.
Rossini M, Gatti D, Adami S. Involvement of WNT/beta-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 2013;93:121–32.
Funding
This work was supported by the Guangxi Key R&D Project (Guike AB18050008), Guangxi Science and Technology Program (2018GXNSFAA294116, 2018GXNSFAA138074), High-level Innovation team and Outstanding Scholars Program of Colleges and Universities in Guangxi: innovative team of basic and Clinical Comprehensive Research on Bone and Joint degenerative Diseases, Scientific Research Project of High-level talents in the affiliated Hospital of Youjiang Medical College for nationalities (R20196301 and R20196306), and Open Project of Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases.
Author information
Affiliations
Contributions
YT, KL, and JL conceived the project, designed and supervised the experiments. KL and JL wrote the paper. CY, CW, and JZ performed the experiments and analyzed the data. QL, FH, and FL helped with the cell-cultured experiments and immunoblotting analysis. YL, JC, FZ, and CH helped prepare the figures and finished the IHC/IF analysis.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Yang, C., Wang, C., Zhou, J. et al. Fibronectin 1 activates WNT/β-catenin signaling to induce osteogenic differentiation via integrin β1 interaction. Lab Invest 100, 1494–1502 (2020). https://doi.org/10.1038/s41374-020-0451-2
Received:
Revised:
Accepted:
Published:
Issue Date:
Further reading
-
Effect of Wenxia Changfu Formula Combined With Cisplatin Reversing Non-Small Cell Lung Cancer Cell Adhesion-Mediated Drug Resistance
Frontiers in Pharmacology (2020)